Home | Site Map | About | Contact 
  The scientific approach to weight loss and maintenance. Indepenent, hype-free research.
 
Weight Loss Guide
 Weight Loss Basics
 Diets & Dieting
 Drug Therapy
 Supplements
 Weight Loss Surgery
 Tools & Calculators
 
News & Research
 Weight Loss News
 Published Studies
   > Drugs
   > Diets
   > Supplements
   > Surgery
   > Lifestyle
 Clinical Trials
 
 
 
 
 
 
 
   
You are here: Published Weight Loss Studies >

Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue.

Author: Ciaraldi TP, Oh DK, Christiansen L, Nikoulina SE, Kong AP, Baxi S, Mudaliar S, Henry RR

Author affiliation: Veterans Affairs San Diego Healthcare System, San Diego, CA 92161, USA.

Publication date & source: 2006.11, Am J Physiol Endocrinol Metab., 291(5):E891-8. Epub 2006 Jun 6.

Publication type: Clinical Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

Glycogen synthase kinase-3 (GSK-3) is a ubiquitous kinase implicated in both insulin action and adipogenesis. To determine how these multiple roles may relate to insulin resistance, we studied the regulation of GSK-3 protein expression and phosphorylation in skeletal muscle and isolated adipocytes from nonobese healthy control (HC), obese control (OC), and obese type 2 diabetic (OT2D) subjects. At baseline there were no differences in the GSK-3 protein expression in adipocytes. OC subjects underwent a 6-mo caloric restriction resulting in a 7% decrease in body mass index (BMI) and a 21% improvement in insulin-stimulated whole body glucose disposal rate (GDR). GSK-3alpha and GSK-3beta expression decreased in adipocytes (P < 0.05), whereas GSK-3alpha protein expression increased in skeletal muscle (P < 0.05). OT2D subjects were treated with troglitazone or metformin for 3-4 mo. After troglitazone treatment GDR improved (P < 0.05) despite an increase in BMI (P < 0.05), whereas metformin had no significant effect on GDR. There was no significant change in GSK-3 expression in adipocytes following troglitazone, whereas both GSK-3alpha and -beta were decreased in skeletal muscle (P < 0.05). Metformin treatment had no significant impact on GSK-3 protein expression in either adipocytes or skeletal muscle. Neither treatment influenced GSK-3 serine phosphorylation in skeletal muscle or adipocytes. These results suggest that there is tissue specificity for the regulation of GSK-3 in humans. In skeletal muscle GSK-3 plays a role in control of metabolism and insulin action, whereas the function in adipose tissue is less clear.



Indexes of Weight Loss Research Abstracts
Weight Loss Drugs
Weight Loss Diets
Supplements
Bariatric Surgery
Lifestyle

     
-- advertisements --


Copyright © 2006 by Weight-Loss-Science.com
All inormation is for education purposes only and should not be considered as a medical advice.